Showing results (21-30 of 109) with videos related to
Sort By:
Pageof 11
Annals of Palliative Medicine|May 12, 2021
Critical diagnostic delay associated with unusual presentation of hepatocellular carcinoma (HCC) with orbital metastases: a case reportDaria M Filippini, Alessandro Di Federico, Barbara Lenzi, et al.Investigational New Drugs|August 26, 2021
Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case reportFrancesco Gelsomino, Alessandro Di Federico, Maria Lucia Tardio, et al.Critical Reviews in Oncology/Hematology|October 14, 2020
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinomaGiuseppe Lamberti, Elisa Andrini, Monia Sisi, et al.Journal of Personalized Medicine|August 26, 2022
Molecular Profile and Prognostic Value of <i>BAP1</i> Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database AnalysisAlessandro Rizzo, Riccardo Carloni, Angela Dalia Ricci, et al.Expert Opinion on Investigational Drugs|November 22, 2021
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospectsAlessandro Rizzo, Angela Dalia Ricci, Laura Lanotte, et al.Expert Opinion on Investigational Drugs|June 25, 2021
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?Alessandro Rizzo, Vincenzo Dadduzio, Angela Dalia Ricci, et al.Lung Cancer (Auckland, N.Z.)|February 10, 2023
Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive ReviewMaria Concetta Nigro, Paola Valeria Marchese, Chiara Deiana, et al.Immunotherapy|November 16, 2022
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignanciesElisa Andrini, Alessandro Di Federico, Monia Sisi, et al.Diagnostics (Basel, Switzerland)|January 11, 2024
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC)Laura Fabbri, Alessandro Di Federico, Martina Astore, et al.Translational Lung Cancer Research|April 11, 2022
<i>EGFR</i>-<i>RAD51</i> gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literatureAlessandro Di Federico, Marco Filetti, Arianna Palladini, et al.Pageof 11